Financings Of The Fortnight: Biotech IPO Trends Continue With Supernus’ Offering – Haircuts, Insider Buys
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financing activity by Argos, Telstar, Castlight Health and Transcept.
You may also be interested in...
$100 Million Venture Round Will Enable Castlight To Branch Out Further
The health care cost transparency firm, which has raised $181 million to date, hopes to grow its commercialization team, add features to its service and expand its reach.
Bright-Eyed And Bushy Tailed: Purdue Launches Intermezzo
Purdue Pharma launched Transcept Pharmaceutical’s Intermezzo, a low-dose sublingual tablet version of the generic sleep aid zolpidem, for middle-of-the-night awakenings April 5. Priced at a wholesale acquisition cost of $6.45 per tablet, the drug could face an uphill commercial road competing against generics.
Transcept Gains Long-Delayed Approval Of Intermezzo
Indication for insomnia characterized by middle-of-the-night awakening followed by difficulty returning to sleep is a first.